TwinStrand Biosciences Announces Second U.S. Patent Trial and Appeal Board Decision Upholding All Claims of TwinStrand’s ‘127 Patent
Business Wire•15/10/2026•16:01 ET
0
Key Highlights
- ➤PTAB again upheld all 30 challenged claims of TwinStrand’s ’127 patent
- ➤Guardant Health failed to establish unpatentability after Federal Circuit remand
- ➤August 2026 judgment awarded TwinStrand and UW more than $245.2 million
- ➤Guardant Health must pay 6% ongoing royalties through March 2033
- ➤Separate USPTO re-examination of TwinStrand’s ’631 patent remains ongoing
Expert Statements
Chad Waite, Chair of the TwinStrand board of directors
“Twice now the Patent Trial and Appeal Board has examined Guardant Health’s challenge to the ‘127 patent, most recently under the precise framework identified by the Federal Circuit, and the outcome remains unchanged”
Chad Waite, Chair of the TwinStrand board of directors
“This Final Written Decision is a substantial, meaningful step forward for our team. We stand unwaveringly behind the intellectual property at the core of Duplex Sequencing and will continue to seek victory against willful infringement of our patent rights.”
TwinStrand Biosciences Announces Second U.S. Patent Trial and Appeal Board Decision Upholding All Claims of TwinStrand’s ‘127 Patent
Following Federal Circuit remand, the PTAB again rules in favor of the University of Washington and TwinStrand on all 30 claims of the ’127 patent challenged by Guardant Health
Get started
Create a free account to read the full story.